Unichem Laboratories
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Unichem Laboratories is navigating a transformative phase under the leadership of Mr. Pabitrakumar Bhattacharyya, focusing on a globally competitive, export-oriented model that has resulted in 98.5% of sales coming from international markets. This strategic pivot, coupled with a partnership with Ipca Laboratories, enhances operational efficiency and cost management, which is crucial for maintaining stable profit margins amid competitive pricing pressures in the generic drug market. Vista's forecast anticipates accelerating revenue growth, supported by Unichem's expansion into high-value therapeutic segments and a robust product pipeline. However, the company faces challenges from global supply chain volatility and raw material constraints, which could impact production and margins. The favorable macroeconomic environment in India, characterized by stable inflation and strong manufacturing activity, provides a supportive backdrop for Unichem's growth. Over the next 12-24 months, key opportunities include leveraging the growing demand for contract manufacturing services and expanding market share in regulated markets, while watchpoints include the potential impact of supply chain disruptions and pricing pressures. Overall, Vista's outlook reflects a balanced view of Unichem's growth potential against the backdrop of industry dynamics and macroeconomic conditions
Why We Like This Stock
- Strategic alignment with Ipca Laboratories enhances operational efficiency and cost management
- Focus on high-value therapeutic segments and a robust product pipeline supports revenue growth
- Favorable macroeconomic conditions in India bolster the company's growth trajectory
Things To Watch Out For
- Global supply chain volatility poses risks to production and margins
- Intense competition in the generic drug market may pressure pricing and profitability
- Raw material supply constraints could hinder operational capabilities
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,785 | 2,111 | 2,202 | 2,416 | 2,789 |
| Profit Before Tax (Cr.) | -29 | 154 | 90 | 156 | 164 |
| PBT Margin | -1.6% | 7.3% | 4.1% | 6.5% | 5.9% |
| Net Profit (Cr.) | -43 | 136 | 114 | 117 | 123 |
| Earnings Per Share | -6.1 | 19.3 | 16.2 | 16.6 | 17.4 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in Asia, Europe, Africa, CIS, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, formulations, bulk drugs, and chemicals. It serves distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.